Overview
The Counter lab studies the molecular mechanisms that underly to the onset of human cancers, with the goal to prevent cancer initiation or progression. The lab uses ultra-senstitive sequencing platforms and proteomic-coupled CRISPR/Cas9 screens to elucidate the factors that mold the mutational patterns selected to initiate the process of tumorigenesis. See https://counter.labs.duke.edu/ for further details.
Current Appointments & Affiliations
George Barth Geller Distinguished Professor of Pharmacology
·
2021 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Professor of Pharmacology and Cancer Biology
·
2011 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Assistant Professor in Radiation Oncology
·
2020 - Present
Radiation Oncology,
Clinical Science Departments
Professor of Cell Biology
·
2022 - Present
Cell Biology,
Basic Science Departments
Member of the Duke Cancer Institute
·
2002 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
The essential clathrin adapter protein complex-2 is tumor suppressive specifically in vivo.
Journal Article Nat Commun · March 6, 2025 The microenvironment is a rich source of new cancer targets. We thus used a targeted single-guide RNA library to screen a panel of human pancreatic cancer lines for genes uniquely affecting tumorigenesis. Here we show inactivation of the Adapter Protein co ... Full text Link to item Citep53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis.
Journal Article PLoS One · 2024 Mice engineered with a G12D versus Q61R mutation in Kras exhibited differences in tumorigenesis. Namely, the incidence or grade of oral or forestomach squamous epithelial lesions was more prevalent in the KrasG12D background while hematolymphopoietic disea ... Full text Link to item CiteAbstract LB263: An in vivo unbiased screen identifies clathrin adaptor protein complex-2 as a novel tumor suppressor
Conference Cancer Research · April 14, 2023 AbstractPancreatic ductal adenocarcinoma (PDAC) is almost uniformly lethal. It is thus imperative to find new therapeutic approaches to treat this disease. While whole genome CRISPR/Cas9 screens have success ... Full text CiteRecent Grants
Duke Research Training Program in Surgical Oncology
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029Duke University Program in Environmental Health
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2019 - 2029Regulation of fertility and reproduction by codon usage: a Drosophila model
ResearchCollaborator · Awarded by National Institutes of Health · 2024 - 2029View All Grants
Education, Training & Certifications
McMaster University (Canada) ·
1996
Ph.D.
McMaster University (Canada) ·
1990
B.S.